Date of Publication: 29-Jan-2026
INTELLIGENCE OVERVIEW
Agency: US FDA
Regulatory authorities have issued updated guidance on Clinical Decision Support (CDS) software, clarifying how such tools are regulated when used to support healthcare decision-making and patient management .
Industry Impact
This guidance has important implications for digital health companies, software developers, and pharmaceutical stakeholders:
- Clarifies which CDS functions fall under medical device regulation and which may be exempt
- Emphasizes transparency, explainability, and user independence in clinical decision-making
- Reduces regulatory uncertainty for AI- and algorithm-based health software
- Supports faster innovation while maintaining patient safety and regulatory compliance
Overall, the guidance provides greater regulatory predictability, enabling companies to design, classify, and commercialize CDS solutions more efficiently within the healthcare ecosystem.